1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
insider
insider
Articles 

Versant Venture Management, LLC Buys Gritstone Oncology Inc, Sells Veracyte Inc, Audentes Therapeutics Inc, CymaBay Therapeutics Inc

July 12, 2019 | About:

San Francisco, CA, based Investment company Versant Venture Management, LLC (current portfolio) buys Gritstone Oncology Inc, sells Veracyte Inc, Audentes Therapeutics Inc, CymaBay Therapeutics Inc during the 3-months ended 2019Q2, according to the most recent filings of the investment company, Versant Venture Management, LLC. As of 2019Q2, Versant Venture Management, LLC owns 8 stocks with a total value of $343 million. These are the details of the buys and sells.

For the details of Versant Venture Management, LLC's stock buys and sells, go to https://www.gurufocus.com/guru/versant+venture+management%2C+llc/current-portfolio/portfolioportfolio

These are the top 5 holdings of Versant Venture Management, LLC
  1. CRISPR Therapeutics AG (CRSP) - 4,248,888 shares, 58.32% of the total portfolio.
  2. Veracyte Inc (VCYT) - 2,410,815 shares, 20.03% of the total portfolio. Shares reduced by 33.33%
  3. Gritstone Oncology Inc (GRTS) - 3,102,929 shares, 10.07% of the total portfolio. New Position
  4. Audentes Therapeutics Inc (BOLD) - 553,916 shares, 6.11% of the total portfolio. Shares reduced by 31.03%
  5. Ocular Therapeutix Inc (OCUL) - 2,215,384 shares, 2.84% of the total portfolio.
New Purchase: Gritstone Oncology Inc (GRTS)

Versant Venture Management, LLC initiated holding in Gritstone Oncology Inc. The purchase prices were between $9.2 and $15.7, with an estimated average price of $11.46. The stock is now traded at around $12.28. The impact to a portfolio due to this purchase was 10.07%. The holding were 3,102,929 shares as of .

Reduced: Veracyte Inc (VCYT)

Versant Venture Management, LLC reduced to a holding in Veracyte Inc by 33.33%. The sale prices were between $22.1 and $28.56, with an estimated average price of $24.94. The stock is now traded at around $28.27. The impact to a portfolio due to this sale was -9.94%. Versant Venture Management, LLC still held 2,410,815 shares as of .

Reduced: Audentes Therapeutics Inc (BOLD)

Versant Venture Management, LLC reduced to a holding in Audentes Therapeutics Inc by 31.03%. The sale prices were between $35.12 and $41, with an estimated average price of $38.42. The stock is now traded at around $34.30. The impact to a portfolio due to this sale was -3.21%. Versant Venture Management, LLC still held 553,916 shares as of .

Reduced: CymaBay Therapeutics Inc (CBAY)

Versant Venture Management, LLC reduced to a holding in CymaBay Therapeutics Inc by 49.87%. The sale prices were between $6.05 and $13.66, with an estimated average price of $11.36. The stock is now traded at around $6.81. The impact to a portfolio due to this sale was -2.37%. Versant Venture Management, LLC still held 543,753 shares as of .



Here is the complete portfolio of Versant Venture Management, LLC. Also check out:

1. Versant Venture Management, LLC's Undervalued Stocks
2. Versant Venture Management, LLC's Top Growth Companies, and
3. Versant Venture Management, LLC's High Yield stocks
4. Stocks that Versant Venture Management, LLC keeps buying

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:


Performances of the stocks mentioned by insider


User Generated Screeners


pjmason14Momentum
pascal.van.garsseHigh FCF-M2
kosalmmuse6
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
kosalmmuseNice
kosalmmusehan
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK